Site for ARST1431: A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI Torisel NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Rms
  • Age: Between 0 - 40 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have sufficient tissue available for the required biology study. 2) Adequate liver function. 3) Adequate bone marrow function.

You may not be eligible for this study if the following are true:

  • 1) Patients who have previously received temsirolimus, another mTOR inhibitor, or any other investigational agent. 2) Patients who have received any chemotherapy (excluding steroids) and/or RT prior to this enrollment. 3) Patients with uncontrolled hyperglycemia and patients with uncontrolled hyperlipidemia. 4) Lactating females who plan to breastfeed their infants.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.